Global NASH Market Opportunity Analysis And Forecasts To 2026

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

August 10, 2017 /MarketersMedia/ —

NASH Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for NASH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

NASH pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Sample copy is available at: https://www.marketinsightsreports.com/reports/080919922/opportunityanalyzer-nash-opportunity-analysis-and-forecasts-to-2026/inquiry

Companies Involved in NASH Development are Gilead Sciences, Intercept Pharmaceuticals, Genfit SA, Allergan Plc, Galectin Therapeutics, Galmed Pharmaceuticals, Inventiva Pharma, Novo Nordisk, Conatus Pharmaceuticals, Novartis, Immuron Limited, Cirius Therapeutics

Our Data estimates the 2016 sales for the NASH market at approximately $618m across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Over the course of the 10-year forecast period, the NASH market will grow at a Compound Annual Growth Rate (CAGR) of 45.0% across the 7MM. The US and Japanese markets are both anticipated to grow significantly, recording CAGRs of 48.1% and 50.7%, respectively, while the 5EU will record a CAGR of 30.6%. At the end of 2026, the US will account for around 88% of global sales, while the 5EU and Japan will account for around 10% and 2% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of NASH in the region, as well as the launch of more pipeline agents in this region.

The NASH pipeline guide also reviews of key players involved in therapeutic development for NASH and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes.

Purchase Report at https://www.marketinsightsreports.com/report/purchase/080919922?mode=su

Scope of this report:

• Overview of NASH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
• Topline NASH market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
• Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting NASH therapeutics sales in the 7MM.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
• Analysis of the current and future market competition in the global NASH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Business insights delivered by this report are:-

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NASH therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Contact Info:
Name: Diane Conrad
Email: [email protected]
Organization: Market Insights Reports

Source URL: http://marketersmedia.com/global-nash-market-opportunity-analysis-and-forecasts-to-2026/227526

For more information, please visit https://www.marketinsightsreports.com/reports/080919922/opportunityanalyzer-nash-opportunity-analysis-and-forecasts-to-2026

Source: MarketersMedia

Release ID: 227526